Document Detail

Effects of growth reduction therapy using high-dose 17beta-estradiol in 26 constitutionally tall girls.
MedLine Citation:
PMID:  16584515     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The efficacy and safety of height-limiting therapy with high-dose 17beta-oestradiol in girls with constitutionally tall stature (CTS) are controversial. We evaluated the effectiveness of high-dose 17beta-oestradiol in premenarchal girls with CTS treated until their bone age reached 14 years. DESIGN: We retrospectively reviewed the medical records of the girls managed between 1989 and 2000 with high-dose 17beta-estradiol for CTS with a predicted final height greater than +3SDs. PATIENTS: Twenty-six girls met our inclusion criteria. At baseline, mean chronological age was 12.06 +/- 1.51 years and mean height was 171.1 +/- 6.5 cm with a height standard deviation score of 4.5 +/- 0.24, and mean predicted final height was 183.0 +/- 4.2 cm. Treatment was stopped when bone age reached 14 years; mean treatment duration was 1.62 +/- 0.76 years. MEASUREMENTS: The following were obtained at 6-month intervals: height, body weight, Tanner stage, bone age, plasma cholesterol and triglycerides, plasma glucose and side effects. A mailed questionnaire on final height and satisfaction was sent 2 years after treatment discontinuation (response rate, 24/26). Results Final height was significantly (P < 0.001) reduced, by 2.4 +/- 3.2 cm, as compared to predictions. High-dose 17beta-estradiol therapy decreased growth velocity and significantly increased skeletal maturation (P < 0.001). Linear growth after treatment discontinuation was 3.3 +/- 1.9 cm. No serious side effects were recorded. Most of the patients were satisfied with the treatment. CONCLUSION: High-dose 17beta-estradiol was moderately effective in reducing final height and should probably be reserved for selected patients, particularly as knowledge on potential long-term side effects is lacking.
U Radivojevic; E Thibaud; D Samara-Boustani; C Duflos; M Polak
Related Documents :
10560995 - Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for th...
24807335 - Repeat midurethral sling compared with urethral bulking for recurrent stress urinary in...
19362675 - Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induc...
17635755 - Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone...
12243435 - Effect of modified ultrafiltration on the inflammatory response in paediatric open-hear...
24402595 - Absorbable mesh augmentation compared with no mesh for anterior prolapse: a randomized ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  64     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-04     Completed Date:  2006-07-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  423-8     Citation Subset:  IM    
Department of Paediatric Endocrinology and Gynaecology, Necker-Enfants Malades Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Body Height / drug effects
Depression, Chemical
Drug Administration Schedule
Estradiol / administration & dosage*,  therapeutic use
Growth Disorders / drug therapy*,  psychology
Patient Satisfaction
Retrospective Studies
Treatment Outcome
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phenotypic variability in children with growth hormone deficiency associated with posterior pituitar...
Next Document:  A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in...